LP
AVDL

LMR Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

LMR Partners’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,500
Closed -$147K – 1027
2022
Q4 		$147K Hold
20,500
– – ﹤0.01% 1018
2022
Q3 		$103K Hold
20,500
– – ﹤0.01% 1050
2022
Q2 		$50K Hold
20,500
– – ﹤0.01% 1160
2022
Q1 		$140K Hold
20,500
– – ﹤0.01% 1165
2021
Q4 		$166K Buy
+20,500
New +$187K ﹤0.01% 1089

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

LMR Partners's AVDL Position: Q1 2023 in Review

LMR Partners sold out of Avadel Pharmaceuticals (AVDL) in Q1 2023, closing a stake of 20,500 shares — an estimated $147K sold.

LMR Partners first reported a position in AVDL in Q4 2021 and held it in 5 quarters. The position peaked at $166K in Q4 2021. 93 funds tracked by Wall St. Rank hold AVDL as of Q1 2023.

  • LMR Partners reported no remaining Avadel Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • LMR Partners sold 20,500 Avadel Pharmaceuticals shares in Q1 2023, an estimated $147K.
  • LMR Partners first reported a position in Avadel Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • LMR Partners's Avadel Pharmaceuticals position peaked at $166K in Q4 2021.
  • 93 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2023.

Based on LMR Partners's 13F filing for Q1 2023, filed 15 May 2023.